Core Insights - In 2024, China approved 48 innovative drugs for market entry, ranking second globally, just behind the United States with 50 approvals. In the first half of this year, the National Medical Products Administration approved 43 innovative drugs, marking a 59% year-on-year increase [1] Policy Guidance - Beijing has implemented a series of pioneering reforms in the pharmaceutical and health sector, including the establishment of green channels for rare disease drug approvals and optimizing clinical trial reviews. These measures aim to create a favorable environment for high-quality industry development [2] - The Beijing Municipal Science and Technology Commission has introduced 32 new measures to support the high-quality development of innovative pharmaceuticals and medical devices [2] - Chengdu has also rolled out specific policies to support the biopharmaceutical industry, focusing on drug and device R&D innovation and enhancing clinical research quality [2] Innovation Ecosystem - Chengdu's Tianfu International Biotech City is a key hub for the biopharmaceutical industry, housing 108 clinical research drugs, including 63 in clinical stages. The "Wutong Plan" launched by Chengdu High-tech Zone offers a comprehensive service list for the pharmaceutical health industry [3] - Jiangsu province has established a robust innovation ecosystem, exemplified by the production of the world's first dual-target weight-loss drug, which was approved in just 16 months [4] Comprehensive Innovation Efforts - Jiangsu has concentrated resources in policy, funding, and talent to strengthen its innovative platforms and tackle key technological challenges in the biopharmaceutical sector [5][6] - The National Biopharmaceutical Technology Innovation Center is focusing on critical technology R&D and public platform construction, with 66 projects already initiated [6] Capital Support - The capital market is increasingly supporting innovative drug development, with Beijing's Changping District establishing a multi-faceted investment framework, including a 200 billion yuan pharmaceutical investment fund [7] - The Zhongguancun Life Science Park in Changping has become a hub for cell and gene therapy, with over 20 companies advancing their products into clinical research [7] - Jiangsu's Shengsheng Biopharmaceutical Co. has committed to significant R&D investments, increasing its budget from 20 billion yuan in the first five years to nearly 80 billion yuan in the subsequent five years [7] Industry Layout - Under the dual support of policies and funding, various regions are accelerating their focus on cutting-edge fields, enhancing both the innovation and industrial chains [8] - The Suzhou Biopharmaceutical Industrial Park has gathered over 620 innovative pharmaceutical companies and more than 35,000 R&D talents, establishing a strong foundation for drug development and high-end medical devices [8]